In vitro and in vivo evaluation of dihydropyrimidinone C-5 amides as potent and selective α1A receptor antagonists for the treatment of benign prostatic hyperplasia

…, KL Glass, KE Rittle, KF Gilbert, TG Steele…

Index: Steele, Thomas G.; Coburn, Craig A.; Patane, Michael A.; Bock, Mark G. Tetrahedron Letters, 1998 , vol. 39, # 51 p. 9315 - 9318

Full Text: HTML

Citation Number: 195

Abstract

α1 Adrenergic receptors mediate both vascular and lower urinary tract tone, and α1 receptor antagonists such as terazosin (1b) are used to treat both hypertension and benign prostatic hyperplasia (BPH). Recently, three different subtypes of this receptor have been identified,